CJC-1295 + Ipamorelin 10 mg is an investigational blend that combines two growth-hormone secretagogues with distinct pharmacological profiles. CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH); it is a modified GHRH(1-29) with a drug-affinity complex (DAC) that covalently binds to albumin. This bioconjugation extends its biological half-life to roughly 6–8 days, with published studies reporting plasma GH elevations of 2–10-fold over baseline for six days and IGF-1 elevations sustained for up to 28 days following a single bolus administration. CJC-1295 is studied as a model for maintaining basal GH and IGF-1 signalling under sustained-release pharmacokinetics.

Ipamorelin is a five-amino-acid growth hormone secretagogue receptor (GHSR-1a) agonist. It mimics ghrelin to initiate rapid, pulsatile GH release, yet it is one of the most selective GHRPs, producing minimal activation of cortisol, ACTH and prolactin pathways. Its effects peak within about an hour and its elimination half-life is approximately two hours, resulting in a sharp GH pulse that fades quickly. Preclinical and clinical literature examines Ipamorelin's pulsatile GH and IGF-1 stimulation as a model for studying GH-axis dynamics.

When co-presented, CJC-1295 and Ipamorelin provide dual-pathway modulation of the hypothalamic-pituitary axis. The long-acting GHRH analogue delivers a sustained baseline signal, while the ghrelin-mimetic supplies acute GH pulses, yielding a release pattern that more closely approximates endogenous GH secretion rhythms in research models. The combination is studied to investigate GH-axis pulsatility, IGF-1 signalling, and downstream metabolic and skeletal-muscle signalling pathways. Supplied exclusively for controlled laboratory research on growth-hormone biology; not for human or veterinary use.